Yen‐Hwa Chang
National Yang Ming Chiao Tung University · 71 works · 7,360 citations · h-index 21
Top works
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Are There Useful CT Features to Differentiate Renal Cell Carcinoma From Lipid-Poor Renal Angiomyolipoma?
- Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
- Immunohistochemical and molecular genetic profiling of acquired cystic disease‐associated renal cell carcinoma
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
- Clinicopathological and molecular characterisation of papillary renal neoplasm with reverse polarity and its renal papillary adenoma analogue
- Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
- Lymphangioma of male exogenital organs.
- The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder
- Renal Oncocytoma: Clinical Experience of Taipei Veterans General Hospital
- Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder
- Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
- Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
- Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells
- XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans General Hospital